SCA
FATE icon

Secor Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Secor Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,469
Closed -$134K – 464
2018
Q4 		$134K Buy
+10,469
New +$146K 0.02% 442

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Secor Capital Advisors's FATE Position: Q1 2019 in Review

Secor Capital Advisors sold out of Fate Therapeutics (FATE) in Q1 2019, closing a stake of 10,469 shares — an estimated $134K sold.

Secor Capital Advisors first reported a position in FATE in Q4 2018 and held it in 1 quarter. The position peaked at $134K in Q4 2018. 123 funds tracked by Wall St. Rank hold FATE as of Q1 2019.

  • Secor Capital Advisors reported no remaining Fate Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 10,469 Fate Therapeutics shares in Q1 2019, an estimated $134K.
  • Secor Capital Advisors first reported a position in Fate Therapeutics in Q4 2018 and held it in 1 quarter.
  • Secor Capital Advisors's Fate Therapeutics position peaked at $134K in Q4 2018.
  • 123 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.